Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07314346) titled 'Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone' on Dec. 18, 2025.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Atea Pharmaceuticals, Inc.
Condition:
Healthy Volunteer Study
Intervention:
Drug: Buprenorphine/Naloxone + BEM/RZR
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: December 2025
Target Sample Size: 32
Countries of Recruitment:
United States
To know more, visit https://clin...